182 results
Page 5 of 10
8-K
EX-10.3
72mzey0w
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm
S-8
yj6l6
27 Mar 20
Registration of securities for employees
8:38am
S-8
EX-23.1
sxk dwwkk3
27 Mar 20
Registration of securities for employees
8:38am
8-K
EX-99.1
wmpcwewzq r0lw
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
vxvvy
27 Mar 20
AVB-500 Phase 1b dose escalation ongoing at 20 mg/kg dose in platinum resistant ovarian cancer with potential for topline data in summer 2020
8:05am
8-K
EX-99.2
wgh2wiip6ls66y
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
7xmz2azxyszuowqjdpb7
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-99.1
5twal s4gbx3w
18 Feb 20
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
8:10am
8-K
EX-10.3
hwuqpd
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.1
mrfqk pwidc8ja
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-10.4
7h165ey2e5ao
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-99.1
wym 4d30nid
2 Dec 19
Other Events
5:18pm
8-K
EX-1.1
64w3chbh
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
424B5
x2r1lz28
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
hzlwi7at8dd462eg2356
26 Nov 19
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.2
n5cjfr
20 Nov 19
Other Events
7:05am